AXLRx Book a callCommission
Twenty minutes with a consultant, before anything is commissioned.Book a scoping call →

Mark W

Commercial Analyst · Oncology · Metabolic · Rare Disease · Immunology · Neurology · Pulmonology

MW

Mark W is a Commercial Analyst at AXLRx, working across competitive-intelligence, disease-landscape and KOL-mapping briefs. He maps the competitive set and the institutional influence network behind an indication, applying the verify-or-drop standard so every figure and every named centre traces to a live source. His focus spans rare and specialty markets across the US, UK and GCC.

Analyses reviewed (55)

CI · US US NSCLC Competitive Intelligence Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry. CI · US US Obesity Competitive Intelligence Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality. CI · US US Type 2 Diabetes Competitive Intelligence Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access. DL · US US ATTR Amyloidosis Disease Landscape Tc-PYP scintigraphy, not biopsy, is now the diagnostic gate in ATTR amyloidosis. This maps the ATTR-CM versus ATTR-PN split and the wild-type/hereditary divide across a largely undiagnosed population. DL · US US IgA Nephropathy Disease Landscape US IgA nephropathy has shifted from RAS-blockade supportive care to five disease-modifying therapies. This maps the epidemiology and the biopsy-and-proteinuria diagnostic gate that still controls who reaches them. CI · US US Myasthenia Gravis Competitive Intelligence Three novel mechanisms in 24 months — FcRn antagonists vs C5 inhibitors, and the AChR+ vs MuSK+ line that segments the market. DL · US US Gaucher Disease Disease Landscape Gaucher type 1 epidemiology, the Ashkenazi Jewish founder burden, GBA1 genotype–phenotype, and the 20-fold Parkinson's risk. CI · US US Gaucher Disease Competitive Intelligence Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot. DL · US US Sickle Cell Disease Disease Landscape SCD epidemiology, genotype mix, VOC and organ-damage burden, and the 22-year life-expectancy gap across the US in-market population. CI · US US Spinal Muscular Atrophy Competitive Intelligence Three mechanisms chase one SMN target: a one-time $2.125M gene therapy, chronic intrathecal ASO, and daily oral. Newborn screening resets the battlefield. P&HTA · US US Fabry Disease Payer & HTA A genetic test gates oral migalastat, and IV enzyme replacement sits in Part B. Fabrazyme has no US biosimilar, and the IRA's orphan-drug exclusion shields it from Medicare price negotiation. P&HTA · US US Atopic Dermatitis Payer & HTA Topical-then-biologic step-therapy, JAK black-box PA gates, ICER's dupilumab-aligned and JAK-discount verdicts, and why Dupixent is not IRA-selected. DL · US US Alzheimer's Disease Disease Landscape US Alzheimer's staging, the amyloid-confirmation diagnostic pathway, and the FDA-cleared plasma pTau-217 blood test resizing the addressable pool. CI · US US COPD Competitive Intelligence Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier. DL · US US Plaque Psoriasis Disease Landscape Psoriasis affects about 3.0% of US adults, roughly 7.55 million people. Only the moderate-to-severe minority reaches the systemic and biologic therapies that define the commercial market. P&HTA · US US Breast Cancer HR+/HER2- Payer & HTA The price ceiling for HR+/HER2- oral therapies is now set directly by the government. Palbociclib was selected for Medicare negotiation with a 50% cut, $15,741 to $7,871, effective 2027. Access runs through Part D and commercial prior authorization, and newer targeted agents face biomarker-gated coverage with cost-effectiveness ratios far above accepted thresholds. CI · GCC GCC IgA Nephropathy Competitive Intelligence Novel IgAN agents are registered across the GCC but not yet formulary-listed. Nephrology specialist centres and the private hospital market are the fastest access channel, while biopsy capacity limits diagnosis. CI · GCC GCC Pompe Disease Competitive Intelligence Nexviazyme beat Lumizyme on 6-minute-walk distance in COMET, but NPHC has set no switch criteria. So 80-120 GCC ERT patients mostly stay on the 2006-era standard. LR · UK UK Fabry Disease Launch Readiness The £144M NHS Fabry market is the largest in Europe, and already has two established agents. An ADA-positive or female-heterozygote niche, not general ERT improvement, is the only viable UK entry point. CI · UK UK Fabry Disease Competitive Intelligence Pegunigalsidase's suboptimal-responder recommendation (TA915) reshapes NHS-commissioned Fabry therapy. It sets oral migalastat against IV enzyme replacement across the UK treated population. DL · UK UK Hereditary Angioedema Disease Landscape UK HAE Alliance genetic testing, an 87% attack-rate reduction on lanadelumab, and the NICE TA606 prophylaxis standard defining NHS management. P&HTA · UK UK PNH Payer & HTA Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route (TA698 and TA1000). The real payer question is how fast the NHS converts patients from IV ravulizumab to oral iptacopan, not which drug got the easier appraisal at the ordinary £20,000–£30,000/QALY bar. HTA · UK UK Breast Cancer HR+/HER2- HTA Strategy Model NICE accepts palbociclib, ribociclib, and abemaciclib as comparators for each other. No trial has ever tested any of them head-to-head against exemestane plus everolimus, the older endocrine-based comparator regimen they effectively replaced. LR · US US PNH Launch Readiness Binding constraint: beat iptacopan's oral bar in the EVH-anaemia cohort anti-C5 can't resolve — inside a pricing ceiling iptacopan already set. LR · GCC GCC Fabry Disease Launch Readiness Both approved Fabry ERTs are already NPHC-covered in the GCC, so the constraint is finding an unaddressed niche. That means the 30-50 patient ADA-positive cohort, or the HEK-assay bottleneck that locks non-KFSH&RC patients out of oral therapy. CI · UK UK Hereditary Angioedema Competitive Intelligence England's NICE has issued three positive technology appraisals funding HAE prophylaxis since 2019 (TA606, TA738, TA1101). The two newest MHRA-licensed agents, donidalorsen and sebetralstat, remain in NICE appraisal with no confirmed final NHS funding decision. LR · US US IgA Nephropathy Launch Readiness Binding constraint: eGFR-confirmed evidence beats a second accelerated approval on UPCR surrogate data alone. PSM · UK UK PNH Pricing Strategy Model NICE has cleared every modern PNH anti-complement therapy through the standard £20,000-30,000 Technology Appraisal route. From ravulizumab to crovalimab, none used the more generous Highly Specialised Technologies threshold, and each went via a confidential patient access scheme. P&HTA · UK UK Fabry Disease Payer & HTA Migalastat's HST4 recommendation in 2016 was the first oral mutation-specific rare disease therapy NICE approved. Agalsidase beta was never formally appraised at all. Together they underpin an estimated £144M NHS Fabry programme, with a £70-130K/patient/year switch incentive still unrealised at scale. LR · US US Myasthenia Gravis Launch Readiness Binding constraint: address FcRn-inadequate responders or claim a serostatus niche — efgartigimod sets both the clinical and ICER pricing bar. DL · GCC GCC Spinal Muscular Atrophy Disease Landscape GCC SMA incidence runs 1:6,000–8,000 births, with newborn screening now covering up to 90% in leading states. An 800–1,200-patient pre-NBS-era Type 2/3 cohort defines the chronic-therapy opportunity. LR · US US Fabry Disease Launch Readiness The ADA-positive suboptimal-agalsidase-responder niche (200–400 US patients) is Fabry's only clean pre-launch opening. P&HTA · GCC GCC Spinal Muscular Atrophy Payer & HTA SMA is the most mature rare-disease access model in the GCC. All three modalities are NPHC-covered, with Zolgensma's outcomes-based milestone rebate the GCC-first template other programmes follow. DL · UK UK IgA Nephropathy Disease Landscape UK Renal Registry data, the ACEi/ARB-first Renal Association pathway, and the NHS economic case for novel agents built on £40–50M annual ESRD cost. LR · US US Alzheimer's Disease Launch Readiness Two anti-amyloid agents already sit inside CMS's coverage-with-evidence-development registry. A new entrant inherits that gate and must price inside ICER's benchmark to avoid Aduhelm's fate. LR · US US Type 2 Diabetes Launch Readiness Tirzepatide's 41% new-GLP-1 share and semaglutide's SELECT label set the efficacy and label bar. A new entrant must clear both while an IRA-reset price anchor is closing in behind it. P&HTA · GCC GCC Pompe Disease Payer & HTA NPHC's well-established Pompe programme still gates avalglucosidase behind a 12-month failed-response switch criterion. Sanofi is pursuing NPHC first-line approval to bypass it. DL · GCC GCC Fabry Disease Disease Landscape Arabian Peninsula founder mutations, the female diagnosis gap, and the HEK assay bottleneck limiting oral chaperone therapy access across the GCC. KOL · GCC GCC Pompe Disease KOL Mapping Six to eight named metabolic centres across the GCC hold ERT infusion capacity for Pompe disease. KFSH&RC leads with roughly 120 patients over 15 years. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it. PFM · GCC GCC IgA Nephropathy Patient Flow Model An estimated 8,000-12,000 GCC IgAN patients narrow to fewer than 30% ever biopsied, then to zero on novel therapy. No agent is SFDA-registered as of 2024. The funnel gap, not the prevalence estimate, is what a GCC patient flow model has to size. KOL · UK UK Dravet Syndrome KOL Mapping Six NHS centres concentrate the UK's refractory Dravet syndrome cohort. Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds and Newcastle. The British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission, and that institutional network is what this workbook sizes first, not a roster of named physicians. P&HTA · DE DE PNH Payer & HTA Iptacopan's orphan-drug status let it clear Germany's AMNOG process with an established additional benefit and no comparator dossier at all. Ravulizumab's only PNH-specific G-BA review found no added benefit. CI · UK UK Sickle Cell Disease Competitive Intelligence Crizanlizumab's EMA/MHRA withdrawal leaves a VOC-prevention gap. Casgevy's NICE recommendation is the watershed NHS gene-therapy access event — Lyfgenia has no UK regulatory status. DL · GCC GCC IgA Nephropathy Disease Landscape IgAN diabetes-masking effect, the kidney biopsy bottleneck, and the ESRD progression gap across GCC nephrology practice. LR · GCC GCC Hereditary Angioedema Launch Readiness HAE prophylaxis barely exists as a category in the GCC. Under 15% of patients are on any prophylaxis versus 35-40% in the US, making this category creation, not competitive share capture. KOL · GCC GCC Spinal Muscular Atrophy KOL Mapping Four designated GCC centres carry nearly all regional SMA gene-therapy and specialist referral activity. KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi. This workbook sizes that institutional concentration before any individual name enters it. P&HTA · GCC GCC IgA Nephropathy Payer & HTA IgA nephropathy has no NPHC programme at all in the GCC. Access runs entirely through hospital pharmacy committees or private insurance, gated by a biopsy available at fewer than 20 GCC centres. PSM · US US Breast Cancer HR+/HER2- Pricing Strategy Model Ibrance's Medicare-negotiated price takes effect a full year before Kisqali's and Verzenio's. Three clinically equivalent drugs, staggered IRA negotiation cycles, means Pfizer sets the reference point Novartis and Lilly then have to negotiate against. KOL · UK UK Hereditary Angioedema KOL Mapping Five NHS specialist centres manage more than 90% of UK HAE patients. Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure. KOL · UK UK Fabry Disease KOL Mapping Royal Free London's National Fabry Service was NICE's appointed clinical expert twice over. It advised on both migalastat's HST4 and pegunigalsidase alfa's TA915, across a network of five named NHS lysosomal storage disorder centres. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it. KOL · UK UK Myasthenia Gravis KOL Mapping A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK carries UK myasthenia care. That network, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it. KOL · GCC GCC ATTR Amyloidosis KOL Mapping KFSH&RC maintains the only GCC-wide ATTRv genetic registry and houses the region's nuclear cardiology programme. Fewer than 8 named cardiology and scintigraphy centres region-wide, spanning KAMC, AUH, HMC Doha, and OCCI Muscat, define a small institutional field this workbook sizes before any individual name enters it. KOL · GCC GCC IgA Nephropathy KOL Mapping GCC IgA nephropathy expertise concentrates in five named tertiary centres. Roughly 300 practising nephrologists work the region, of whom 30 to 50 carry glomerular-disease subspecialty interest. This workbook sizes that concentrated institutional base before any individual name enters it. DL · GCC GCC ATTR Amyloidosis Disease Landscape ATTR-CM diagnostic abyss, Arabian Peninsula TTR variant registry, and the referral-pathway delay across GCC cardiology centres. KOL · GCC GCC PNH KOL Mapping Seven institutions across Riyadh, Jeddah, Dubai and Abu Dhabi hold the GCC's confirmed PNH caseload. Just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it.